EVGN - Evogene Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.0700
-0.0100 (-0.93%)
At close: 3:21PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.0800
Open1.1000
Bid1.0400 x 3000
Ask1.0700 x 3000
Day's Range1.0600 - 1.1000
52 Week Range0.7500 - 1.8300
Volume1,359
Avg. Volume20,180
Market Cap26.928M
Beta (5Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-0.7030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Evogene Reports First Quarter 2020 Financial Results
      PR Newswire

      Evogene Reports First Quarter 2020 Financial Results

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its financial results for the first quarter, ended March 31, 2020.

    • Evogene Launches Its New Branding to Reflect the Company's Expanded Vision and New Business Model
      PR Newswire

      Evogene Launches Its New Branding to Reflect the Company's Expanded Vision and New Business Model

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces today its rebranding. The new corporate identity reflects the company's expanded vision and new business model.

    • Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2020
      PR Newswire

      Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2020

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries by utilizing cutting edge computational biology technologies, announces today that it will release its financial results for the first quarter 2020 on Tuesday, May 26, 2020.

    • Evogene Publishes Letter to Shareholders
      PR Newswire

      Evogene Publishes Letter to Shareholders

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries, by utilizing cutting edge computational biology technologies, announces today a letter to the shareholders from President and CEO, Ofer Haviv.

    • Evogene Files Annual Report for the Year Ended December 31, 2019
      PR Newswire

      Evogene Files Annual Report for the Year Ended December 31, 2019

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the U.S. Securities and Exchange Commission (the "SEC").

    • Corteva Agriscience and AgPlenus Announce Collaboration for the Development of Novel Herbicides
      PR Newswire

      Corteva Agriscience and AgPlenus Announce Collaboration for the Development of Novel Herbicides

      Corteva Agriscience (NYSE: CTVA), a leading pure-play agriculture company, and AgPlenus, a subsidiary of Evogene Ltd., (NASDAQ: EVGN) (TASE: EVGN), today announced that they have entered into a multi-year collaboration for the development of novel herbicides. The collaboration will combine Corteva's strengths in crop protection product discovery and development with AgPlenus' expertise in designing effective and sustainable crop protection products using predictive biology.

    • The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
      Benzinga

      The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

      Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS Medical School to develop a COVID-19 vaccine for Singapore) * Cue Biopharma Inc (NASDAQ: CUE) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Ocular Therapeutix Inc (NASDAQ: OCUL)(reacted to its preliminary fourth-quarter results and interim data from a Phase 1 study evaluating its eye implant OTX-TKI in patients with wet age-related macular degeneration) * Quest Diagnostics Inc (NYSE: DGX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)(CEO Leonard Schleifer reportedly told CNBC the company hopes to produce COVID-19 treatment candidate that could be ready for human testing by August) * Revolution Medicines Inc (NASDAQ: RVMD) (IPOed mid-February) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX)(reacted to the company's fourth-quarter results) * Syneos Health Inc (NASDAQ: SYNH) * Viela Bio Inc (NASDAQ: VIE)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 4) * Alterity Therapeutics Ltd (NASDAQ: ATHE) * AngioDynamics, Inc. (NASDAQ: ANGO) * Aptevo Therapeutics Inc (NASDAQ: APVO) * CASI Pharmaceuticals Inc (NASDAQ: CASI) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Evogene Ltd (NASDAQ: EVGN)(reacted to fourth-quarter results) * Evolus Inc (NASDAQ: EOLS)(reacted to comments by Korean drug maker Medytox about an ITC case brought up by the company against Daewoong and partner Evolus on intellectual property related to Medytox' botulinum toxin) * Mylan NV (NASDAQ: MYL) * Orthofix Medical Inc (NASDAQ: OFIX) * Passage Bio Inc (NASDAQ: PASG)(IPOed last week) * Titan Medical Inc. (NASDAQ: TMDI)See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Co-Diagnostics' COVID-19 Detection Kit Demand Surges Co-Diagnostics Inc (NASDAQ: CODX) said demand, both domestic and international, surged for its COVID-19 detection kits in recent weeks, leading to increased product shipments. The increase comes after the FDA changed its policy Feb. 20 and the number of cases testing positive for the disease burgeoned worldwide.The stock was surging 27.17% to $15.26 in pre-market trading.Castle Biosciences Gets First Patent For Skin Cancer Gene Expression Profile Test Skin cancer diagnostic company Castle Biosciences Inc (NASDAQ: CSTL) said the U.S. patent office has issued it the first U.S. patent related to the DecisionDx -Melanoma gene expression profile test for patients with cutaneous melanoma.FDA Accepts Trevena's Resubmitted NDA for Pain Drug Trevena Inc (NASDAQ: TRVN) said the FDA has acknowledged the receipt of and accepted the resubmitted NDA for intravenous oliceridine, its lead investigational asset, for the management of moderate-to-severe acute pain. The PDUFA date has been set for Aug. 7.In pre-market trading, shares were rising 12.35% to 91 cents.Can-Fite To Explore Treatment For COVID-19 Can-Fite BioPharma Ltd. (NASDAQ: CANF) said it is exploring a collaboration to explore if its investigational asset Piclidenoson, being evaluated for autoimmune inflammatory disease, is effective against coronavirus following reports that rheumatoid arthritis drugs have been introduced for the treatment of the same.The stock was jumping 26.28% to $1.97 in pre-market trading.RA Medical Says NYSE Accepts Plan to Regain Compliance RA Medical Systems Inc (NYSE: RMED) said the NYSE has accepted the company's business plan to regain compliance with the NYSE listing standards. Late last year, the company was notified by the NYSE regarding flouting of listing standards pertaining to average market capitalization being less than $50 million over a recent consecutive 30 days.MacroGenomics' Chief Medical Officer Resigns to Pursue Another Opportunity MacroGenics Inc (NASDAQ: MGNX) announced the resignation of Jon Wigginton as its SVP, Clinical Development & Chief Medical Officer, effective March 27, as he pursues a new opportunity. The role will be assigned on an interim basis to Ezio Bonvini, who is currently serving as SVP, Research and Chief Scientific Officer, the company said.Morphosys To Issue Additional Shares For Subscription By Incyte As Part of Tafasitamab Licensing Deal Morphosys Ag (NASDAQ: MOR) said its Management Board has resolved to increase the share capital of the company by issuing 907,441 new ordinary shares from the authorized capital to facilitate purchase of 3.63 million ADSs by Incyte Corporation (NASDAQ: INCY). The newly issued shares represent about 2.84% of the registered share capital of MorphoSys prior to the consummation of the capital increase.View more earnings on TRVNIncyte's purchase of ADSs amounting to $150 million or $41.32 per ADS is part of the consideration due to MorphoSys for the former acquiring licensing rights to develop and commercialize the latter's investigational compound tafasitamab.In pre-market trading, MorphoSys shares were slipping 3.70% to $28.89.Earnings Specialty pharma company Opiant Pharmaceuticals Inc (NASDAQ: OPNT), which develops treatment for treating addictions and drug overdose, reported fourth-quarter revenues of $7.7 million compared to $4.8 million in the fourth quarter of 2018. The company reversed to a profit of 20 cents per share from a loss of $2.49 per share last year, while analysts had estimated a loss of $2.13 per share, on average.The stock rallied 17.09% to $13.70 in after-hours trading.Offerings BridgeBio Pharma Inc (NASDAQ: BBIO) priced the upsized offering of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers. The company said the notes will bear interest at a rate of 2.50% per year, payable semi-annually in arrears on March 15 and Sept. 15 of each year. Beginning Sept. 15, 2020.The company estimates to raise net proceeds of about $463.7 million from the offering.On The Radar Earnings * Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) * Xtant Medical Holdings Inc (NYSE: XTNT) (before the market open) * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open) * Obseva SA (NASDAQ: OBSV) (before the market open) * OptiNose Inc (NASDAQ: OPTN) (before the market open) * Caladrius Biosciences Inc (NASDAQ: CLBS) (after the close) * Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the close) * BioNano Genomics Inc (NASDAQ: BNGO) (after the close) * Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the close) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) (after the close)See more from Benzinga * GenMark Spikes Higher On COVID-19 Test Kit Shipment * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * How The COVID-19 Outbreak Is Benefiting Biotech Investors(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Evogene Reports Fourth Quarter and Full Year 2019 Financial Results
      PR Newswire

      Evogene Reports Fourth Quarter and Full Year 2019 Financial Results

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading company in leveraging computational biology to design novel products for life-science-based industries, announces today its financial results for the fourth quarter and full year, ending December 31, 2019.

    • Evogene to Attend in Bank of America 2020 Global Agriculture and Materials Conference
      PR Newswire

      Evogene to Attend in Bank of America 2020 Global Agriculture and Materials Conference

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading company in leveraging computational biology to design novel products for life-science-based industries including: human health, agriculture and industrial applications, announces today that Eran Kosover, CEO of AgPlenus, Evogene's subsidiary designing effective and sustainable crop protection products, will attend in the BofA 2020 Global Agriculture and Materials Conference taking place February 26th – 27th at the Conrad in Fort Lauderdale, FL.

    • Evogene Financial Results for the Fourth Quarter and Full Year of 2019 Earnings Announcement Schedule
      PR Newswire

      Evogene Financial Results for the Fourth Quarter and Full Year of 2019 Earnings Announcement Schedule

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading company in leveraging computational biology to design novel products for life-science-based industries including: human health, agriculture and industrial applications, announces today that it will release its financial results for the fourth quarter and full year of 2019 on Wednesday, March 4, 2020.

    • Canonic Announces an Agreement With Hadassah Medical Center for Pre-Clinical Studies to Support the Development of Canonic's Medical Cannabis Products
      PR Newswire

      Canonic Announces an Agreement With Hadassah Medical Center for Pre-Clinical Studies to Support the Development of Canonic's Medical Cannabis Products

      Canonic, a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) and (TASE: EVGN) focused on the development of medical cannabis products, announces today an agreement with Hadasit, Hadassah Medical Center Technology Transfer Company, for pre-clinical studies to support the development of anti-inflammatory medical Cannabis products as part of its Precise product program. The work will be conducted by the laboratory of Prof. Reuven Or in Hadassah Medical Center (Ein Kerem, Israel), screening Canonic's Cannabis core collection in inflammatory in-vitro models. These studies are expected to support the development of Canonic's unique Cannabis varieties with anti-inflammatory properties.

    • Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program
      PR Newswire

      Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program

      Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for the scale-up production of its drug candidates, microbial consortia BMC121 & BMC127 for its Immuno-Oncology program. This agreement will accelerate the Company's Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies.

    • Hedge Funds Have Never Been More Bullish On Evogene Ltd. (EVGN)
      Insider Monkey

      Hedge Funds Have Never Been More Bullish On Evogene Ltd. (EVGN)

      Is Evogene Ltd. (NASDAQ:EVGN) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]

    • Lavie Bio Announces Advancement in Its Product Development Pipeline for Wheat Bio-stimulants
      PR Newswire

      Lavie Bio Announces Advancement in Its Product Development Pipeline for Wheat Bio-stimulants

      Leading wheat bio-stimulant candidate for spring wheat, exhibiting consistent performance, advancing to 'development stage 2', in line with Lavie Bio's commercialization plans for 2022 REHOVOT, Israel ...

    • Evogene Reports Third Quarter 2019 Financial Results
      PR Newswire

      Evogene Reports Third Quarter 2019 Financial Results

      Conference call and webcast: November 13th, 9:00 am ET REHOVOT, Israel , Nov. 13, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products ...

    • Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program
      PR Newswire

      Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program

      Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127 REHOVOT, Israel , Nov. 12, 2019 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative ...

    • Canonic Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products
      PR Newswire

      Canonic Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products

      REHOVOT, Israel, Nov. 6, 2019 /PRNewswire/ -- Canonic, a wholly owned subsidiary of Evogene Ltd. (EVGN) (EVGN.TA) focused on the development of medical cannabis products, announces today the initiation of its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. The initiation of cannabis cultivation follows: (1) successfully importing widely genetically diverse cannabis lines originating from different territories, (2) establishment of cannabis dedicated R&D facilities, including greenhouses, a molecular lab and tissue culture rooms and (3) receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency (IMCA).

    • Biomica to Collaborate With Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic Resistant Bacteria
      PR Newswire

      Biomica to Collaborate With Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic Resistant Bacteria

      The company has in-licensed IP and knowhow generated by Prof. Ada E. Yonath, Nobel Prize winner, who will advise Biomica on the program REHOVOT, Israel , Oct. 23, 2019 /PRNewswire/ --   Biomica, an emerging ...

    • Evogene Financial Results for the Third Quarter of 2019 Earnings Announcement Schedule
      PR Newswire

      Evogene Financial Results for the Third Quarter of 2019 Earnings Announcement Schedule

      REHOVOT, Israel , Oct. 23, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will ...

    • Biomica Announces Advancement to Pre-Clinical Studies in its Inflammatory Bowel Disease Program
      PR Newswire

      Biomica Announces Advancement to Pre-Clinical Studies in its Inflammatory Bowel Disease Program

      REHOVOT, Israel, Oct. 2, 2019 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (EVGN) and (EVGN.TA), announces today the initiation of pre-clinical studies for BMC321 & BMC322, two rationally-designed microbial consortia aimed to reduce inflammation for the treatment of Inflammatory Bowel Disease (IBD). Biomica's program aims to develop a novel microbiome-based drug for IBD that triggers multiple mechanisms for the reduction of intestinal inflammation.

    • Lavie Bio, Evogene's Ag-Biologicals Subsidiary, Announces the Nomination of Industry Experts to its Board of Directors
      PR Newswire

      Lavie Bio, Evogene's Ag-Biologicals Subsidiary, Announces the Nomination of Industry Experts to its Board of Directors

      The nomination of industry experts is expected to support the company's management in execution of its product development and commercialization roadmap REHOVOT, Israel , Sept. 11, 2019 /PRNewswire/ -- ...

    • Canonic to Present at CannX, 4th International Medical Cannabis Conference in Tel Aviv
      PR Newswire

      Canonic to Present at CannX, 4th International Medical Cannabis Conference in Tel Aviv

      REHOVOT, Israel , Sept. 4, 2019 /PRNewswire/ -- Canonic, a fully owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), developing medical cannabis products, announces today that Dr. Arnon Heyman ...

    • Corteva Agriscience to Invest in Evogene's Agriculture Biologicals Subsidiary, Lavie Bio
      PR Newswire

      Corteva Agriscience to Invest in Evogene's Agriculture Biologicals Subsidiary, Lavie Bio

      WILMINGTON, Del. and REHOVOT, Israel, Aug. 7, 2019 /PRNewswire/ -- Corteva, Inc. (NYSE:CTVA), a leading pure-play agriculture company, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Corteva will make an investment in Evogene's agriculture biologicals subsidiary, Lavie Bio (Lavie). The transaction includes the exchange of all shares of Corteva's wholly owned subsidiary Taxon Biosciences along with an equity investment by Corteva in Lavie. As consideration for the Taxon Biosciences shares and equity investment, Corteva will be issued approximately 30 percent of Lavie's equity while Evogene will hold approximately 70 percent of Lavie's equity.

    • Evogene Reports Second Quarter of 2019 Financial Results
      PR Newswire

      Evogene Reports Second Quarter of 2019 Financial Results

      Conference call and webcast: July 31st, 9:00 am ET REHOVOT, Israel , July 31, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for ...

    • Evogene Amends its Collaboration Agreement With Bayer to Include Genome Editing Targets
      PR Newswire

      Evogene Amends its Collaboration Agreement With Bayer to Include Genome Editing Targets

      Amended agreement follows positive results in corn stalk rot fungal disease control REHOVOT, Israel , July 16, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company ...